Adipocyte Fatty Acid-Binding Protein 4 is Altered in Growth Discordant Dichorionic, but not in Monochorionic Twins.
A-FABP
adipocyte fatty acid-binding protein 4
adipokine
cord blood
fetal programming
twins
Journal
Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997
Informations de publication
Date de publication:
01 Apr 2020
01 Apr 2020
Historique:
received:
21
07
2019
accepted:
18
12
2019
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
epublish
Résumé
The fetal period has a critical and long-lasting impact on the regulation of metabolic processes and a life-long predisposition for obesity and metabolic syndrome. The exact mechanisms are unknown, but epigenetic regulation likely plays a major role. Twins represent an excellent model to study these mechanisms, as they share the same intrauterine environment and similar or even the same genetic information. We examined cord blood levels of adipocyte fatty-acid binding protein 4 (A-FABP or FABP4), a novel adipokine correlated with obesity and metabolic disease in children and adults. To examine A-FABP levels in the cord blood of twins with concordant and discordant growth and in singletons with intrauterine growth restriction (IUGR). Cohort study of 36 twin pairs (25 growth concordant and 11 growth discordant), and 42 singleton pregnancies (28 IUGR and 13 normally grown controls, 1 HELLP). Cord blood A-FABP levels measured by enzyme-linked immunosorbent assay (ELISA). A-FABP levels were higher in the smaller of growth discordant dichorionic (DC) twins versus their co-twins (109.46 ± 62.80 ng/mL vs. 72.93 ± 36.66 ng/mL, Increased A-FABP levels might be associated with an increased metabolic risk in growth-restricted (twins) and prematurely born infants.
Identifiants
pubmed: 32258957
doi: 10.1210/jendso/bvz031
pii: bvz031
pmc: PMC7094755
doi:
Types de publication
Journal Article
Langues
eng
Pagination
bvz031Informations de copyright
© Endocrine Society 2019.
Références
Hepatology. 2009 Jun;49(6):1926-34
pubmed: 19475694
Trends Pharmacol Sci. 2015 Jul;36(7):461-70
pubmed: 26022934
Am J Clin Nutr. 2011 Jan;93(1):19-26
pubmed: 21106915
Metabolism. 2009 Mar;58(3):275-7
pubmed: 19217438
Regul Pept. 2011 Jun 7;168(1-3):69-72
pubmed: 21477622
J Pediatr Endocrinol Metab. 2011;24(11-12):921-8
pubmed: 22308843
Am J Hypertens. 2008 May;21(5):582-6
pubmed: 18437151
Atherosclerosis. 2007 Nov;195(1):e150-8
pubmed: 17553506
Obes Rev. 2007 Mar;8 Suppl 1:37-40
pubmed: 17316299
Diabetes Care. 2011 Sep;34(9):2061-6
pubmed: 21775757
BMJ. 1990 Nov 17;301(6761):1111
pubmed: 2252919
Clin Chem. 2006 Mar;52(3):405-13
pubmed: 16423904
Internist (Berl). 2014 Jun;55(6):687-97; quiz 698
pubmed: 24831682
J Endocrinol Invest. 2012 Jun;35(6):562-5
pubmed: 21791968
J Clin Endocrinol Metab. 2018 Mar 1;103(3):1015-1023
pubmed: 29325128
Exp Clin Endocrinol Diabetes. 2009 Jun;117(6):241-50
pubmed: 19358089
Eur J Endocrinol. 2010 Dec;163(6):887-93
pubmed: 20870707
Metabolism. 2010 Jan;59(1):33-7
pubmed: 19699495
Eur J Endocrinol. 2009 Jan;160(1):33-8
pubmed: 18849305
Diabetes Care. 2007 Oct;30(10):2667-72
pubmed: 17620449
Clin Endocrinol (Oxf). 2012 Jan;76(1):2-11
pubmed: 21951069
Clin Endocrinol (Oxf). 2007 Mar;66(3):434-9
pubmed: 17302880
Diabetologia. 2013 Jan;56(1):10-21
pubmed: 23052058
Horm Res Paediatr. 2010;74(1):56-61
pubmed: 20424419
Eur J Endocrinol. 2008 Feb;158(2):197-201
pubmed: 18230826
Int J Mol Sci. 2014 Oct 29;15(11):19760-76
pubmed: 25356508
Metabolism. 2009 Jun;58(6):798-802
pubmed: 19368945
Cytokine. 2013 May;62(2):322-6
pubmed: 23545215
J Clin Endocrinol Metab. 2017 May 1;102(5):1606-1613
pubmed: 28324040
Clin Med Insights Cardiol. 2015 Feb 02;8(Suppl 3):23-33
pubmed: 25674026